世界慢性閉塞性肺疾患市場規模のシェア、競争環境およびトレンド分析レポート：タイプ別（慢性気管支炎、肺気腫）、治療タイプ別（薬剤、気管支拡張薬単剤療法、短時間作用型β2アゴニスト（SABAS）、長時間作用型β2アゴニスト（LABAS）、抗コリン薬、抗炎症薬、経口および吸入ステロイド、抗ロイコトリエン、手術、肺容量減少手術（LVRS）、肺移植、ブラ切除術、その他、酸素療法）、エンドユーザー別（病院、在宅医療施設、診療所、その他）：2024-2032年の機会分析および業界予測
レポートID : ROJP1024304 |
発行日 : 2024年10月 |
フォーマット : 
: 
: 
無料サンプル
LIST OF TABLES
TABLE 1 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SYNOPSIS, 2023-2032
TABLE 2 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET ESTIMATES & FORECAST, 2023-2032 (USD MILLION)
TABLE 3 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY REGION, 2023-2032 (USD MILLION)
TABLE 7 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 9 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 10 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 11 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 12 US: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 13 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 14 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 15 CANADA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 16 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 17 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 18 LATIN AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 19 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 20 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 21 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 22 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 23 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 24 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 25 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 26 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 27 EASTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 28 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 29 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 30 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY COPD TYPE, 2023-2032 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY TREATMENT TYPE, 2023-2032 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET, BY END USER, 2023-2032 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET
FIGURE 4 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COPD TYPE, 2020 (%)
FIGURE 5 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY TREATMENT TYPE, 2020 (%)
FIGURE 6 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY END USER, 2020 (%)
FIGURE 7 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE BY REGION, 2020 (%)
FIGURE 8 NORTH AMERICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 9 EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY REGION, 2020 (%)
FIGURE 10 WESTERN EUROPE: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 11 ASIA-PACIFIC: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 MIDDLE EAST & AFRICA: CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 14 ABBOTT LABORATORIES.: KEY FINANCIALS
FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE
FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE
FIGURE 17 ALMIRALL: KEY FINANCIALS
FIGURE 18 ALMIRALL: SEGMENTAL REVENUE
FIGURE 19 ALMIRALL: REGIONAL REVENUE
FIGURE 20 ASTELLAS PHARMA: KEY FINANCIALS
FIGURE 21 ASTELLAS PHARMA: SEGMENTAL REVENUE
FIGURE 22 ASTELLAS PHARMA: REGIONAL REVENUE
FIGURE 23 ASTRAZENECA: KEY FINANCIALS
FIGURE 24 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 25 ASTRAZENECA: REGIONAL REVENUE
FIGURE 26 BOEHRINGER INGELHEIM: KEY FINANCIALS
FIGURE 27 BOEHRINGER INGELHEIM: SEGMENTAL REVENUE
FIGURE 28 BOEHRINGER INGELHEIM: REGIONAL REVENUE
FIGURE 29 CIRCASSIA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 30 CIRCASSIA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 31 CIRCASSIA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 32 GLAXOSMITHKLINE PLC: KEY FINANCIALS
FIGURE 33 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE
FIGURE 34 GLAXOSMITHKLINE PLC: REGIONAL REVENUE
FIGURE 35 NOVARTIS AG: KEY FINANCIALS
FIGURE 36 NOVARTIS AG: SEGMENTAL REVENUE
FIGURE 37 NOVARTIS AG: REGIONAL REVENUE
FIGURE 38 PFIZER, INC.: KEY FINANCIALS
FIGURE 39 PFIZER, INC.: SEGMENTAL REVENUE
FIGURE 40 PFIZER, INC.: REGIONAL REVENUE
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS
FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE
FIGURE 43 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE
